Top

Published in:

01-06-2019 | Breast Cancer | Epidemiology

Trends in utilization of hypofractionated whole breast irradiation (HF-WBI) in triple negative breast cancer (TNBC): a national cancer database (NCDB) analysis

Authors: Stephanie R. Rice, Steven J. Feigenberg, Muhammad Hamza, Jason K. Molitoris, Søren M. Bentzen, Katherine H. R. Tkaczuk, Paula M. Rosenblatt, Emily C. Bellavance, Elizabeth M. Nichols

Published in: Breast Cancer Research and Treatment | Issue 2/2019

Abstract

Purpose

We sought to identify trends over time with respect to the use of hypofractionated whole breast irradiation (HF-WBI) in women with triple negative breast cancer (TNBC) in the national cancer database (NCDB).

Methods

Trends in utilization of HF-WBI in women diagnosed with T1-2N0 TNBC in the NCDB between 2008 and 2013 were analyzed. Case-matched luminal A women were used for comparison. Variables included age, race, year of diagnosis, insurance status, income quartile, receipt of neoadjuvant chemotherapy, and institution (academic vs. community). Chi square, logistic regression, and multivariate analysis was performed.

Results

Utilization of HF-WBI among the 53,269 TNBC women identified steadily increased from 4.7% in 2008 to 14.0% in 2013 for women with TNBC compared to luminal A cancer whose utilization increased from 7.3 to 23.3% over the same time frame (p < 0.001). On univariate analysis, HF-WBI was associated with increasing age (p < 0.001), Medicare insurance (p < 0.001), race (p = 0.041), diagnosis after 2011 (p < 0.001), higher income quartile (p < 0.001), and treatment at academic institutions (p < 0.001). On multivariate analysis, age (p < 0.001, OR 1.038 per year), income quartile (p = 0.002, OR 1.061 per increase in quartile), treatment at an academic institution (p < 0.001, OR 1.78) significantly increased use of HF-WBI.

Conclusions

Treatment at an academic center and year of diagnosis were most correlated with increased HF-WBI in T1-2N0 TNBC women in the NCDB from 2008 to 2013, followed by increasing age and income. Only 14% of T1-2N0 TNBC women received HF-WBI in 2013. Focus on increased utilization is needed for non-academic centers, lower income, and younger women.

Siegel RL, Miller KD, Jemal A. Cancer statistics (2018) CA Cancer J Clin 2018;68(1):7–30. https://doi.org/10.3322/caac.21442 CrossRefPubMed

Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26(15):2568–2581. https://doi.org/10.1200/JCO.2007.13.1748 CrossRefPubMed

Reis-Filho JS, Tutt ANJ (2008) Triple negative tumours: a critical review. Histopathology 52(1):108–118. https://doi.org/10.1111/j.1365-2559.2007.02889.x CrossRefPubMed

Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948. https://doi.org/10.1056/NEJMra1001389 CrossRefPubMed

Trivers KF, Lund MJ, Porter PL et al (2009) The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 20(7):1071–1082. https://doi.org/10.1007/s10552-009-9331-1 CrossRefPubMedPubMedCentral

Lin NU, Vanderplas A, Hughes ME et al (2012) Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118(22):5463–5472. https://doi.org/10.1002/cncr.27581 CrossRefPubMed

Gonzalez-Angulo AM, Timms KM, Liu S et al (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082–1089. https://doi.org/10.1158/1078-0432.CCR-10-2560 CrossRefPubMedPubMedCentral

Colleoni M, Cole BF, Viale G et al (2010) Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 28(18):2966–2973. https://doi.org/10.1200/JCO.2009.25.9549 CrossRefPubMedPubMedCentral

Isakoff SJ, Mayer EL, He L et al (2015) TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 33(17):1902–1909. https://doi.org/10.1200/JCO.2014.57.6660 CrossRefPubMedPubMedCentral

10.

Silver DP, Richardson AL, Eklund AC et al (2010) Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28(7):1145–1153. https://doi.org/10.1200/JCO.2009.22.4725 CrossRefPubMedPubMedCentral

11.

Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15):4429–4434. https://doi.org/10.1158/1078-0432.CCR-06-3045 CrossRefPubMed

12.

Trialists TS (2008) The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 9(4):331–341. https://doi.org/10.1016/S1470-2045(08)70077-9 CrossRef

13.

Haviland JS, Owen JR, Dewar JA et al (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14(11):1086–1094. https://doi.org/10.1016/S1470-2045(13)70386-3 CrossRefPubMed

14.

Agrawal RK, Aird EGA, Barrett JM et al (2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371(9618):1098–1107. https://doi.org/10.1016/S0140-6736(08)60348-7 CrossRefPubMed

15.

Yarnold J, Ashton A, Bliss J et al (2005) Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 75(1):9–17. https://doi.org/10.1016/j.radonc.2005.01.005 CrossRefPubMed

16.

Owen JR, Ashton A, Bliss JM et al (2006) Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 7(6):467–471. https://doi.org/10.1016/S1470-2045(06)70699-4 CrossRefPubMed

17.

Whelan TJ, Pignol J-P, Levine MN et al (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362(6):513–520. https://doi.org/10.1056/NEJMoa0906260 CrossRefPubMed

18.

Smith BD, Bentzen SM, Correa CR et al (2011) Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol 81(1):59–68. https://doi.org/10.1016/j.ijrobp.2010.04.042 CrossRef

19.

Jagsi R, Falchook AD, Hendrix LH, Curry H, Chen RC (2014) Adoption of hypofractionated radiation therapy for breast cancer after publication of randomized trials. Int J Radiat Oncol Biol Phys 90(5):1001–1009. https://doi.org/10.1016/j.ijrobp.2014.09.032 CrossRefPubMed

20.

Jagsi R, Griffith KA, Heimburger D et al (2014) Choosing wisely? Patterns and correlates of the use of hypofractionated whole-breast radiation therapy in the state of Michigan. Int J Radiat Oncol Biol Phys 90(5):1010–1016. https://doi.org/10.1016/j.ijrobp.2014.09.027 CrossRefPubMed

21.

Gilbo P, Potters L, Lee L (2018) Implementation and utilization of hypofractionation for breast cancer. Adv Radiat Oncol 3(3):265–270. https://doi.org/10.1016/j.adro.2018.04.001 CrossRefPubMedPubMedCentral

22.

Bane AL, Whelan TJ, Pond GR et al (2014) Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Ann Oncol 25(5):992–998. https://doi.org/10.1093/annonc/mdu090 CrossRefPubMed

23.

Smith BD, Bellon JR, Blitzblau R et al (2018) Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol 8(3):145–152. https://doi.org/10.1016/j.prro.2018.01.012 CrossRefPubMed

24.

Bilimoria KY, Stewart AK, Winchester DP, Ko CY (2008) The National cancer data base: a powerful initiative to improve cancer care in the united states. Ann Surg Oncol 15(3):683–690. https://doi.org/10.1245/s10434-007-9747-3 CrossRefPubMedPubMedCentral

25.

Bekelman JE, Sylwestrzak G, Barron J et al (2014) Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008–2013. JAMA 312(23):2542. https://doi.org/10.1001/jama.2014.16616 CrossRefPubMedPubMedCentral

26.

Shaitelman SF, Schlembach PJ, Arzu I et al (2015) Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial. JAMA Oncol 1(7):931–941. https://doi.org/10.1001/jamaoncol.2015.2666 CrossRefPubMedPubMedCentral

27.

Vargas L, Solé S, Solé CV (2018) Cosmesis after early stage breast cancer treatment with surgery and radiation therapy: experience of patients treated in a Chilean radiotherapy centre. Ecancermedicalscience 12:819. https://doi.org/10.3332/ecancer.2018.819 CrossRefPubMedPubMedCentral

28.

Taher AN, El-Baradie MM, Essa H, Zaki O, Ezzat S (2004) Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reactions and cosmetic results. J Egypt Natl Canc Inst 16(3):178–187PubMed

Title: Trends in utilization of hypofractionated whole breast irradiation (HF-WBI) in triple negative breast cancer (TNBC): a national cancer database (NCDB) analysis
Authors: Stephanie R. Rice
Steven J. Feigenberg
Muhammad Hamza
Jason K. Molitoris
Søren M. Bentzen
Katherine H. R. Tkaczuk
Paula M. Rosenblatt
Emily C. Bellavance
Elizabeth M. Nichols
Publication date: 01-06-2019
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 2/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05150-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2019

Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients

Loss of HER2 after HER2-targeted treatment

Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit

Screening for distant metastases in patients with ipsilateral breast tumor recurrence: the impact of different imaging modalities on distant recurrence-free interval

Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up

Health-related quality of life in long-term disease-free breast cancer survivors versus female population controls in Germany

Keynote webinar | Spotlight on antibody–drug conjugates in cancer